Browse our comprehensive collection of market intelligence reports.
The global COVID-19 diagnostics market supports the identification, monitoring, and surveillance of SARS-CoV-2 infections across laboratory, point-of-care, and self-testing environments. The market structure is transitioning from emergency pandemic response toward targeted diagnostic deployment as endemic disease management becomes the dominant healthcare strategy. Demand is increasingly concentrating on high-risk populations, hospitalized patients, immunocompromised individuals, and integrat
The global proteomic biomarkers market supports disease characterization, therapeutic development, patient stratification, and treatment monitoring through the identification and quantification of protein-based biomarkers. The market functions as a critical component of precision medicine because proteins directly reflect physiological and pathological changes that cannot always be captured through genomic analysis alone. Demand is increasingly shifting toward high-throughput proteomic platfo
The global prognostic biomarkers market focuses on biomarkers that estimate disease progression, recurrence risk, treatment outcomes, and long-term patient survival across multiple therapeutic areas. These biomarkers support clinical decision-making by stratifying patients according to disease severity rather than predicting immediate therapeutic response. The market is serving oncology as its primary application while expanding into cardiovascular, neurological, autoimmune, and metabolic dis
The global predictive biomarkers market supports precision medicine by identifying biological indicators that forecast patient response to specific therapeutic interventions before treatment initiation. The market is becoming an essential component of clinical decision-making because healthcare providers increasingly rely on molecular evidence to optimize treatment selection while minimizing ineffective therapies. This clinical dependence is driving sustained investments in biomarker discover
The global diagnostic biomarkers market comprises molecular, biochemical, cellular, and histopathological indicators that support disease detection, patient stratification, therapeutic selection, disease monitoring, and treatment response assessment across multiple clinical specialties. The market is functioning as a critical component of precision medicine because biomarkers enable clinicians to identify disease-specific biological changes before clinical symptoms become fully established.</
The Global Colorectal Cancer Companion Diagnostics Market supports treatment selection by identifying molecular biomarkers that predict therapeutic response and resistance in patients with colorectal cancer. The market encompasses molecular assays, immunohistochemistry, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based tests, and bioinformatics solutions that guide precision oncology decisions. Demand is shifting from single-gene testing toward comprehensive biomarker pr
The global breast cancer companion diagnostics market supports precision oncology by identifying predictive biomarkers that guide targeted treatment selection and therapeutic monitoring. The market function is shifting from single-gene testing toward comprehensive molecular profiling because oncologists increasingly require biomarker-driven evidence before initiating high-value targeted therapies. Growing adoption of next-generation sequencing (NGS), multiplex molecular assays, and liquid bio
The global oncology companion diagnostics market supports precision oncology by identifying patients who are most likely to benefit from targeted therapies based on specific molecular and genetic biomarkers. Demand is shifting from single-gene testing toward comprehensive genomic profiling because oncology drug pipelines are expanding across multiple biomarker-defined patient populations. This transition places companion diagnostics at the center of therapeutic decision-making and strengthens
The global immunotherapy companion diagnostics market supports precision oncology by identifying patients who are most likely to benefit from immune checkpoint inhibitors and other immuno-oncology therapies. Companion diagnostics integrate molecular and protein biomarker assessment with therapeutic decision-making, enabling clinicians to improve treatment selection while reducing exposure to ineffective therapies. Demand is shifting toward multiplex biomarker profiling because single-marker t
The global tuberculosis (TB) diagnostics market supports the timely identification of Mycobacterium tuberculosis infection across active disease, latent infection, drug-resistant tuberculosis, and treatment monitoring. Demand is shifting from conventional microscopy and culture toward rapid molecular diagnostics because national tuberculosis elimination programs require earlier case detection, improved drug-resistance identification, and decentralized testing. This transition is incr
The global lung cancer companion diagnostics market supports precision oncology by identifying predictive biomarkers that determine patient eligibility for targeted therapies and immunotherapies. The market function centers on linking molecular test results with regulatory-approved therapeutic decisions, enabling clinicians to select treatments based on tumor-specific genomic alterations rather than histological classification alone. Growing integration of next-generation sequencing (NGS), po
The global HIV diagnostics market supports early disease identification, treatment monitoring, blood safety screening, and public health surveillance across healthcare systems. Demand is shifting from centralized laboratory testing toward decentralized diagnostic platforms because healthcare providers are prioritizing earlier diagnosis, rapid clinical decision-making, and expanded testing coverage among high-risk and underserved populations. This transition is increasing the adoption of rapid